Similar articles

• Remission of disseminated cancer after systemic oncolytic virotherapy.

  Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG, Lowe V, O'Connor MK, Kyle RA, Leung N, Buadi FK, Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A. Russell SJ, et al. Mayo Clin Proc. 2014 Jul;89(7):926-33. doi: 10.1016/j.mayocp.2014.04.003. Epub 2014 May 14. Mayo Clin Proc. 2014. PMID: 24835528 Free PMC article.
• Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.

  Packiriswamy N, Upreti D, Zhou Y, Khan R, Miller A, Diaz RM, Rooney CM, Dispenzieri A, Peng KW, Russell SJ. Packiriswamy N, et al. Leukemia. 2020 Dec;34(12):3310-3322. doi: 10.1038/s41375-020-0828-7. Epub 2020 Apr 23. Leukemia. 2020. PMID: 32327728 Free PMC article. Clinical Trial.
• Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus.

  Deng H, Tang N, Stief AE, Mehta N, Baig E, Head R, Sleep G, Yang XZ, McKerlie C, Trudel S, Stewart AK, McCart JA. Deng H, et al. Leukemia. 2008 Dec;22(12):2261-4. doi: 10.1038/leu.2008.120. Epub 2008 May 29. Leukemia. 2008. PMID: 18509356 No abstract available.
• Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.

  Msaouel P, Dispenzieri A, Galanis E. Msaouel P, et al. Curr Opin Mol Ther. 2009 Feb;11(1):43-53. Curr Opin Mol Ther. 2009. PMID: 19169959 Free PMC article. Review.
• Systemic virotherapy for multiple myeloma.

  Oliva S, Gambella M, Boccadoro M, Bringhen S. Oliva S, et al. Expert Opin Biol Ther. 2017 Nov;17(11):1375-1387. doi: 10.1080/14712598.2017.1364359. Epub 2017 Aug 10. Expert Opin Biol Ther. 2017. PMID: 28796556 Review.